INO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
INO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Inovio Pharmaceuticals's enterprise value is $223.52 Mil. Inovio Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.83 Mil. Therefore, Inovio Pharmaceuticals's EV-to-Revenue for today is 268.65.
The historical rank and industry rank for Inovio Pharmaceuticals's EV-to-Revenue or its related term are showing as below:
During the past 13 years, the highest EV-to-Revenue of Inovio Pharmaceuticals was 1434.89. The lowest was -51.50. And the median was 25.55.
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
As of today (2024-05-16), Inovio Pharmaceuticals's stock price is $12.79. Inovio Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.04. Therefore, Inovio Pharmaceuticals's PS Ratio for today is 345.68.
The historical data trend for Inovio Pharmaceuticals's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inovio Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
EV-to-Revenue | Get a 7-Day Free Trial | 84.25 | 172.86 | 403.63 | 16.95 | 29.34 |
Inovio Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
EV-to-Revenue | Get a 7-Day Free Trial | 16.95 | 2.25 | -4.62 | -38.35 | 29.34 |
For the Biotechnology subindustry, Inovio Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Inovio Pharmaceuticals's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Inovio Pharmaceuticals's EV-to-Revenue falls into.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
Inovio Pharmaceuticals's EV-to-Revenue for today is calculated as:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 223.515 | / | 0.832 | |
= | 268.65 |
Inovio Pharmaceuticals's current Enterprise Value is $223.52 Mil.
Inovio Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.83 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inovio Pharmaceuticals (NAS:INO) EV-to-Revenue Explanation
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
Inovio Pharmaceuticals's PS Ratiofor today is calculated as:
PS Ratio | = | Share Price (Today) | / | Revenue per Share (TTM) |
= | 12.79 | / | 0.037 | |
= | 345.68 |
Inovio Pharmaceuticals's share price for today is $12.79.
Inovio Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.04.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Inovio Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Lota S. Zoth | director | 334 CR 692, BUFFALO GAP TX 79508 |
David B. Weiner | director | 717 BEACOM LANE, MERION STATION PA 19066-1603 |
Simon X Benito | director | 967 LAWRENCE AVE, WESTFIELD NJ 07090 |
Michael John Sumner | officer: Chief Medical Officer | 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462 |
Laurent Humeau | officer: Chief Scientific Officer | C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462 |
Jacqueline Elizabeth Shea | officer: Chief Operating Officer | C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462 |
Peter Kies | officer: CFO | |
Roger D Dansey | director | 21823 30TH DRIVE SE, BOTHELL WA 98021 |
Jong Joseph Kim | director, officer: Chief Executive Officer | 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462 |
Jay Shepard | director | 15977 GRANDVIEW AVENUE, MONTE SERENO CA 95030 |
Ann Calby Miller | director | C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462 |
Wendy L Yarno | director | |
Morton Collins | director | |
George Bickerstaff | director | C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511 |
Niranjan Sardesai | officer: Chief Operating Officer | VGX PHARMACEUTICALS, INC., 450 SENTRY PARKWAY, BLUE BELL PA 19422 |
From GuruFocus
By PRNewswire • 01-03-2024
By PRNewswire • 08-29-2023
By PRNewswire • 10-26-2023
By PRNewswire PRNewswire • 04-26-2023
By PRNewswire • 01-22-2024
By PRNewswire PRNewswire • 04-17-2023
By PRNewswire PRNewswire • 05-10-2023
By PRNewswire PRNewswire • 04-12-2023
By PRNewswire PRNewswire • 06-01-2023
By PRNewswire PRNewswire • 03-03-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.